FDA Warns Consumers Not to Buy or Use Artri and Ortiga Products
The FDA is warning consumers not to purchase or use products marketed with variations of the names “Artri” or “Ortiga” due to potentially dangerous hidden active drug ingredients not listed on the product label. These products are marketed as treatments for arthritis, muscle pain, osteoporosis, bone cancer, and other conditions. These medications are sold on various websites and in some retail stores, making them easily accessible to injured workers who may purchase them to help manage pain. Certain Artri and Ortiga products contained undeclared dexamethasone, diclofenac sodium, and methocarbamol, all which come with safety risks when not used appropriately. Furthermore, these drugs can interact with an individual’s overall drug regimen, leading to additional safety concerns, including drug-drug or drug-disease interactions.
Teligent Pharma Recalls Lidocaine Topical Solution Due to Super Potency
Teligent Pharma issued a recall for two lots of Lidocaine HCl topical solution USP 4% 50ml due to super potency. Lidocaine is used as a local anesthetic, but an increased lidocaine dose could lead to systemic toxicity depending on the duration of treatment and the specific patient. This can result in central nervous system reactions such as hypotension and cardiovascular collapse, along with severe morbidity and even death.
